戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and constipation are known risk factors for fecal incontinence.
2  to guide the initial management of men with fecal incontinence.
3  colon, but 3 were subsequently reversed for fecal incontinence.
4 erformed in 28 women (aged 27-74 years) with fecal incontinence.
5 n adult aged 60 or older with urinary and/or fecal incontinence.
6 udo-obstruction, constipation, diarrhea, and fecal incontinence.
7 ed do not thoroughly assess constipation and fecal incontinence.
8            There was no urinary retention or fecal incontinence.
9 al sphincter muscle as a method for treating fecal incontinence.
10 ntify phenotypes in defecatory disorders and fecal incontinence.
11           Some patients reported symptoms of fecal incontinence.
12                         No patient developed fecal incontinence.
13 s and management of defecatory disorders and fecal incontinence.
14 ledge about the long-term outcome of SNS for fecal incontinence.
15 younger group developed ischemic colitis and fecal incontinence.
16 pproach might be used to treat patients with fecal incontinence.
17 uropathy) are not included within functional fecal incontinence.
18 function ranging from fecal urgency to frank fecal incontinence.
19 an cause urge-related or diarrhea-associated fecal incontinence.
20 pplies to the experience of individuals with fecal incontinence.
21 l surgical option in the treatment of severe fecal incontinence.
22 s to measure severity and quality of life in fecal incontinence.
23 s outcome variables in therapeutic trials of fecal incontinence.
24 risk factors common to both constipation and fecal incontinence.
25 and ileal pouch reconstruction can result in fecal incontinence.
26 o, more sucralfate-treated patients reported fecal incontinence (16% v 34%, respectively; P =.04) and
27 us bowel movements/week and </= 1 episode of fecal incontinence/2 weeks, from study weeks 5-8 (respon
28  55.1% in the placebo group had a history of fecal incontinence; 60.4% and 55.1% in the prucalopride
29 (84%), weight loss (77%), fatigue (71%), and fecal incontinence (62%).
30                                              Fecal incontinence (-8.6 points [95% CI, -16.7 to -0.5 p
31                                  Urinary and fecal incontinence affect 50% or more of nursing home re
32 luding pelvic organ prolapse and urinary and fecal incontinence, affect millions of women globally an
33                                              Fecal incontinence affects between 1% and 16% of women,
34 dverse events included vomiting, urinary and fecal incontinence, agitation, combativeness, a labile l
35 ables determination of the anatomic cause of fecal incontinence, allowing the surgeon to select patie
36 tify ways to counteract the social stigma of fecal incontinence and assist physicians in providing pa
37 has been advocated as therapy for refractory fecal incontinence and for anorectal reconstruction to a
38 d that target anal canal resting pressure in fecal incontinence and hypersensitivity to distention in
39 on of quality-of-life issues associated with fecal incontinence and improved assessment and communica
40                                Both rates of fecal incontinence and obstructed defecation decreased s
41 and advice to patients around the world with fecal incontinence and other gastrointestinal disorders,
42 th dynamic muscle plasty in the treatment of fecal incontinence and total anal reconstruction.
43 % of women (95% CI, 7.3%-10.7%) experiencing fecal incontinence, and 2.9% of women (95% CI, 2.1%-3.7%
44  was the greatest risk factor for developing fecal incontinence, and fecal incontinence was the great
45 enced swallowing difficulties, tinnitus, and fecal incontinence, and he had undergone cataract surger
46 elvic floor disorders (urinary incontinence, fecal incontinence, and pelvic organ prolapse) affect ma
47                             Quality of life, fecal incontinence, and satisfaction with surgery were p
48 diverticulitis, enhanced recovery protocols, fecal incontinence, and single incision laparoscopic sur
49 sorption, anal sphincter dysfunction causing fecal incontinence, and the irritable bowel syndrome.
50 e and/or innervation insufficient to explain fecal incontinence, and/or (3) normal or disordered bowe
51 agnosing functional anorectal disorders (ie, fecal incontinence, anorectal pain, and disorders of def
52                  Separate cost estimates for fecal incontinence are not available.
53               Corresponding data on men with fecal incontinence are sparse.
54 dure for patients with refractory, end-stage fecal incontinence as well as for patients who require a
55 ting of strategies for primary prevention of fecal incontinence associated with childbirth, and furth
56 utcome of sacral nerve stimulation (SNS) for fecal incontinence at 5 years after implantation and to
57 x, constituting moderate to severe leakage), fecal incontinence (at least monthly leakage of solid, l
58  It is recommended that outcome measures for fecal incontinence be more clearly defined, that future
59                               Treatments for fecal incontinence (biofeedback, sphincteroplasty, antid
60 t (biofeedback) has been reported to improve fecal incontinence but has not been compared with standa
61 oaches may benefit a subset of patients with fecal incontinence, but more controlled studies are need
62  encopresis with or without constipation and fecal incontinence caused by anatomic or organic disease
63 creased stool frequency or fewer episodes of fecal incontinence compared to handsewn IPAA, which exci
64 71%, 50%, and 66% for patients with acquired fecal incontinence, congenital incontinence, and total a
65 reviewed recent publications in the areas of fecal incontinence, constipation, single incision and ro
66                       Surgical therapies for fecal incontinence continue to evolve and show promise i
67 gested that psychological symptoms can cause fecal incontinence, data are lacking to support a causat
68 mpounds offering new treatment approaches to fecal incontinence, development and testing of strategie
69               Defecatory disorders including fecal incontinence (FI) are diagnosed on the symptom pat
70 obstructed defecation syndrome (ODS) in 40%, fecal incontinence (FI) in 22%, combination of ODS and F
71 ed prospectively from patients implanted for fecal incontinence (FI) in 7 French centers between Janu
72 ogen levels can contribute to development of fecal incontinence (FI) in women after menopause by alte
73                        Chronic diarrhea with fecal incontinence (FI) is a severe, underreported, and
74                          The epidemiology of fecal incontinence (FI) is incompletely understood.
75 nce 1997, and in Europe for both urinary and fecal incontinence (FI) since 1994.
76 alence of different types and frequencies of fecal incontinence (FI), describe demographic factors, a
77 nd management of common anorectal disorders: fecal incontinence (FI), functional anorectal pain and f
78 l fissures, dyssynergic defecation (DD), and fecal incontinence (FI), which are arguably the most com
79 cutaneous tibial nerve stimulation (PTNS) in fecal incontinence (FI).
80 be as effective as stimulation at the ST for fecal incontinence (FI).
81 rtain chronic illnesses are risk factors for fecal incontinence (FI).
82 ontrolled fecal soiling and leads to passive fecal incontinence (FI).
83            This need is especially great for fecal incontinence, for which there is much less health
84                        Surgical treatment of fecal incontinence has evolved from colostomy and direct
85                                              Fecal incontinence (hazard ratio [HR], 1.78; 95% confide
86 c floor retraining by biofeedback therapy in fecal incontinence; however, the predictive value of imp
87                     Conservative therapy for fecal incontinence improves continence, quality of life,
88 nation of obstructed defecation syndrome and fecal incontinence in 21% and other conditions in 17%.
89  were obstructed defecation syndrome in 40%, fecal incontinence in 22%, combination of obstructed def
90 ses the diagnosis and treatment of pediatric fecal incontinence in 4 main categories: (1) Functional
91 und is extremely useful in the evaluation of fecal incontinence in men.
92 hysical activity to improve constipation and fecal incontinence in nursing home residents.
93                     The most common cause of fecal incontinence in otherwise healthy women is damage
94                              The etiology of fecal incontinence in women is almost exclusively from o
95            Specific diseases associated with fecal incontinence include diabetes, multiple sclerosis,
96 Salvage options for patients with refractory fecal incontinence include passive or electrically stimu
97                  Risks of tumor spillage and fecal incontinence induced by transanal extraction are n
98                                              Fecal incontinence is a challenging condition with numer
99                                   Functional fecal incontinence is a common, but underrecognized symp
100                                              Fecal incontinence is a significant source of morbidity
101                                              Fecal incontinence is a symptom attributable to a variet
102                                   Functional fecal incontinence is defined as the uncontrolled passag
103                             The incidence of fecal incontinence is high in children up to the age of
104 he most important tool in the "treatment" of fecal incontinence is its prevention, which should be th
105 eedback techniques used to treat urinary and fecal incontinence lack standardization.
106 mpered by heterogeneity in the definition of fecal incontinence, lack of consensus on what constitute
107           (4) Children with spina bifida and fecal incontinence may benefit from techniques that teac
108 (health-related quality of life, disability, fecal incontinence), midterm complications (encompass bo
109                                          For fecal incontinence, more significant treatment results w
110                                   Night-time fecal incontinence occurred less frequently in the stapl
111                                              Fecal incontinence occurs when the normal anatomy or phy
112 , and amount of stool loss and the impact of fecal incontinence on coping mechanisms and lifestyle/be
113                                   She denies fecal incontinence or change in stool caliber.
114 ofeedback retraining include the duration of fecal incontinence, pudendal nerve damage, patient age,
115 re reduction (-2.9; 95% CI: -3.7, -2.1), and Fecal Incontinence Quality of Life increased (2.2; 95% C
116 ality of life was assessed with the Rockwood Fecal Incontinence Quality of Life questionnaire.
117 isodes, Cleveland Clinic Incontinence Score, Fecal Incontinence Quality of Life, and anorectal manome
118 Incontinence Score (CCIS)], quality of life [Fecal-Incontinence Quality of Life Questionnaire (FIQL)]
119  All patients were evaluated with the Wexner Fecal Incontinence Questionnaire after stoma closure.
120                                              Fecal incontinence rates improved marginally in both the
121 32.4; P =0.002) and Cleveland Clinic Florida Fecal Incontinence Score (6.4 vs 9.2; P =0.050).
122                            The median Wexner fecal incontinence score was 9 (possible range: 0-20), a
123 ured by LARS score, Cleveland Clinic Florida Fecal Incontinence Score, and 4 study-specific questions
124                                              Fecal incontinence seems to be a problem.
125   Fecal incontinence was evaluated using the Fecal Incontinence Severity Index (FISI).
126 nction was measured quantitatively and using Fecal Incontinence Severity Index (FISI).
127                                The validated Fecal Incontinence Severity Index was added to NHANES in
128 s of the multifaceted mechanisms maintaining fecal incontinence should be incorporated as outcome var
129 r success after implantation was no previous fecal incontinence surgical treatment.
130 el shows promise for significantly improving fecal incontinence symptoms and quality of life.
131 physiologic factors that predict response to fecal incontinence therapy would be helpful in choosing
132 of furthering research activities related to fecal incontinence through the National Institutes of He
133 pacitating fecal urgency and associated urge fecal incontinence (UFI).
134 eir 20s or 30s typically do not present with fecal incontinence until their 50s.
135                                              Fecal incontinence was evaluated using the Fecal Inconti
136                                              Fecal incontinence was initially significantly higher in
137                           The side effect of fecal incontinence was only temporary until the seventh
138 actor for developing fecal incontinence, and fecal incontinence was the greatest risk factor for deve
139         Nausea, diarrhoea, constipation, and fecal incontinence were all much more common (p<0.0001)
140 n January 1995 and January 1998, 37 men with fecal incontinence were evaluated in the John Radcliffe
141                 A total of 171 patients with fecal incontinence were randomized to 1 of 4 groups: (1)
142   Before surgery, 22 patients (32%) reported fecal incontinence, which improved after surgery in 15 c
143  of toileting assistance on the frequency of fecal incontinence, while significant, are less dramatic
144 s by far the most prominent association with fecal incontinence, with a prevalence approaching 50%.
145 recent surgical options for the treatment of fecal incontinence within the context of established the

 
Page Top